INT47626

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 1980
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 9
Disease Relevance 3.79
Pain Relevance 2.13

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Serpinb1b) cytoplasm (Serpinb1b)
Anatomy Link Frequency
upper 1
Serpinb1b (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 129 99.72 Very High Very High Very High
antagonist 87 98.66 Very High Very High Very High
anesthesia 4 98.32 Very High Very High Very High
Inflammation 36 98.08 Very High Very High Very High
corticosteroid 126 97.62 Very High Very High Very High
lidocaine 3 94.84 High High
tolerance 38 92.40 High High
cINOD 1 80.32 Quite High
Inflammatory mediators 13 69.04 Quite High
Potency 1 66.88 Quite High
Disease Link Frequency Relevance Heat
Asthma 421 99.62 Very High Very High Very High
Rhinitis 12 99.28 Very High Very High Very High
INFLAMMATION 51 98.08 Very High Very High Very High
Pulmonary Disease 18 84.84 Quite High
Occupational Lung Diseases 3 75.00 Quite High
Cough 21 64.92 Quite High
Hypersensitivity 14 39.12 Quite Low
Airway Obstruction 84 28.64 Quite Low
Disease 15 15.52 Low Low
Dyspnea 86 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Inhaled indomethacin significantly attenuated EIB.
Negative_regulation (attenuated) of EIB
1) Confidence 0.37 Published 1997 Journal Am. J. Respir. Crit. Care Med. Section Abstract Doc Link 9001307 Disease Relevance 0.32 Pain Relevance 0.11
The results suggested that local anesthesia of the upper and large airways in patients with bronchial asthma can significantly inhibit EIB and significantly decrease VE during moderate exercise.
Negative_regulation (inhibit) of EIB in upper associated with asthma and anesthesia
2) Confidence 0.37 Published 1980 Journal Am. Rev. Respir. Dis. Section Abstract Doc Link 7458056 Disease Relevance 0.30 Pain Relevance 0.57
Pranlukast showed a similar protective effect after 14 days of treatment in a Japanese study.83 Other inhibitors of the activity of leukotrienes such as ziluton, a leukotriene synthesis inhibitor, have also shown beneficial effects in patients with EIB.80 In most countries, only the LTRA montelukast has received approval by drug regulatory agencies for prevention of EIB.
Negative_regulation (prevention) of EIB associated with antagonist
3) Confidence 0.34 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789687 Disease Relevance 0.35 Pain Relevance 0.17
Later in some countries it was given an approval for the treatment of allergic rhinitis and more recently approval for the prevention of EIB.
Negative_regulation (prevention) of EIB associated with rhinitis
4) Confidence 0.34 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789687 Disease Relevance 0.40 Pain Relevance 0.11
The duration that a medication can attenuate EIB is important to many athletics and patients who may exercise at different times of the day or who do not wish to take medication immediately before exercise.
Negative_regulation (attenuate) of EIB
5) Confidence 0.25 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789687 Disease Relevance 0.06 Pain Relevance 0.05
This is true in the majority of studies dating back to the 1980s in patients with EIB.50–53 Although immediately after inhalation there can be demonstrated a modest improvement in FEV1, presumably from a decrease in bronchomotor tone, there is little effect on the prevention of EIB and in the majority of patients they are not used as such.


Negative_regulation (prevention) of EIB
6) Confidence 0.25 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789687 Disease Relevance 0.69 Pain Relevance 0.22
The effect of ICS on airway inflammation in both adults and children when given for at least four weeks will in many cases be enough to decrease or eliminate EIB.54 Therefore, before starting additional medications for EIB, it is important to be certain how well a patient’s asthma is being controlled with the medications they are supposed to be taking.
Negative_regulation (decrease) of EIB associated with asthma, corticosteroid and inflammation
7) Confidence 0.25 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789687 Disease Relevance 0.64 Pain Relevance 0.28
2-agonists for both the prevention of EIB when given prior to the exercise period or post-exercise to reverse the obstruction that has occurred.56 The effect of these medications especially when taken by inhalation is rapid which results in their being the most commonly prescribed for patients with asthma and EIB.
Negative_regulation (prevention) of EIB associated with asthma and agonist
8) Confidence 0.25 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789687 Disease Relevance 0.42 Pain Relevance 0.33
Specifically, it is approved for the prevention of EIB from 2 years of age (Pajaron-Fernandez et al 2006).
Negative_regulation (prevention) of EIB
9) Confidence 0.02 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376066 Disease Relevance 0.61 Pain Relevance 0.29

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox